Sign Up to like & get
recommendations!
0
Published in 2019 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehz748.0350
Abstract: Ibrutinib, a first in class Bruton tyrosine kinase inhibitor, has revolutionized treatment for several B-cell malignancies. However, early data suggested that ibrutinib was associated with supra-ventricular arrhythmias (SVA) and bleeding. Other types of cardiovascular adverse…
read more here.
Keywords:
ibrutinib;
ror ic025;
pharmacovigilance study;
days iqr ... See more keywords